Physician

Erin E Fleener, M.D.

According to 2025 Medicare claims, Erin Fleener, M.D. (NPI: 1295775005) practices medical oncology in the College Station-Bryan, TX market, with the plurality of this provider's patient population coming from Brazos, TX. This provider's primary affiliated billing organization is BRAZOS VALLEY HEMATOLOGY ONCOLOGY ASSOCIATES, PA (NPI: 1376594432; TIN: 742803009) and primary practice location at 77802-2585. Fleener is affiliated with the Baylor Scott & White Quality Alliance (ACO ID: A2542), participating under the MSSP model.

Fleener's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 720 traditional Medicare patients, billed 251,103 HCPCS/CPT codes, and received $3,952,432 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 2,260 prescription claims across 384 beneficiaries totaling $7,326,521 in drug costs, led by Revlimid (Lenalidomide). DME data shows 67 claims. Open Payments data shows 80 records totaling $15,827. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,431,030 to $3,952,432. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,011,771 to $7,326,521. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	431	91,091	$1,431,030
2016	421	147,282	$1,766,176
2017	520	152,282	$2,070,133
2018	530	169,292	$2,987,004
2019	530	170,538	$3,146,089
2020	567	197,052	$3,667,575
2021	574	240,879	$3,595,074
2022	583	261,367	$3,899,410
2023	628	267,561	$4,474,102
2024	720	251,103	$3,952,432

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	160	984	$1,011,771
2016	169	1,100	$1,300,905
2017	205	1,279	$1,947,630
2018	263	1,678	$3,020,185
2019	310	2,008	$3,977,050
2020	308	2,032	$4,098,922
2021	344	2,214	$5,248,199
2022	366	2,288	$5,667,886
2023	348	2,091	$5,849,141
2024	384	2,260	$7,326,521

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	48	$1,959
2016	N/R	16	$644
2017	N/R	26	$9,123
2018	N/R	14	$579
2019	N/R	N/R	N/R
2020	N/R	22	$2,409
2021	N/R	N/R	N/R
2022	N/R	13	$962
2023	N/R	55	$10,078
2024	N/R	67	$2,078

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	176	543	$143
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	370	715	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	146	187	$61
36415	Insertion of needle into vein for collection of blood sample	452	1,703	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	348	1,410	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	47	1,316	$964,858
Calquence	Acalabrutinib Maleate	57	1,710	$787,536
Ibrance	Palbociclib	35	980	$560,931
Pomalyst	Pomalidomide	22	616	$504,010
Verzenio	Abemaciclib	32	896	$446,276

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	23	$866
J8700	Temozolomide, oral, 5 mg	N	N/R	11	$610
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	33	$602

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	78	$2,557	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$13,270	E.R. Squibb & Sons, L.L.C.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Erin E. Fleener, M.D.?

Tedicare shows public-source Medicare data for Erin E. Fleener, M.D. (NPI 1295775005), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Erin E. Fleener, M.D. have ACO affiliation data?

Erin E. Fleener, M.D. is shown with ACO affiliation data for Baylor Scott & White Quality Alliance (MSSP, ACO ID A2542).

What billing organization is linked to Erin E. Fleener, M.D.?

Erin E. Fleener, M.D. is linked to BRAZOS VALLEY HEMATOLOGY ONCOLOGY ASSOCIATES, PA (billing NPI 1376594432) in the available physician profile data.

Does Erin E. Fleener, M.D. have Open Payments data?

Erin E. Fleener, M.D. has 80 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.